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Abstract
Background
The diverse clinical picture of Psoriatic Arthritis (PsA) suggests the need to identify suitable therapies 
to address the different clinical manifestations.
Review
We set out to review the current literature regarding the use of biological therapies for the treatment of 
psoriasis and PsA. Literature searches were performed for different classes of biological agents: Anti-
TNF (Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab), Anti-IL12/IL23 (Ustekinumab), 
Anti-co-stimulatory Molecule (Abatacept), Phosphodiesterase-4-Inhibitor (Apremilast), Anti-IL17 
(Secukinumab, Brodalumab, Ixekizumab), T-Cell Modulators (Alefacept, Efalizumab), Anti-IL6 
(Tocilizumab), Janus-Kinase-Inhibitor (Tofacitinib), Anti-CD20 (Rituximab). Papers with the highest 
level of clinical evidence were analysed to look at responses to psoriasis (as measured by the PASI75 
response), PsA (ACR20 response), and extra-articular manifestations such as enthesitis and dactylitis 
scoring, and nail disease improvement. The effect on radiographic progression and patient quality of 
life was also analysed.
Discussion
The majority of the biologics showed efficacy for skin psoriasis and peripheral arthritis. Efficacy for 
enthesitis, dactylitis and nail disease was seen in some, but only a few improved sacroiliitis and spinal 
disease. 
Conclusion
Recommendations could be made for Ustekinumab or Secukinumab (if at a higher dose or IV) being 
used as a 2nd line biologic in anti-TNF failures, and there is evidence for switching anti-TNF drugs if a 
patient fails their first anti-TNF treatment.
Introduction
The diverse clinical picture of PsA suggests the need to identify suitable therapies to address different 
combinations of clinical manifestations. Tailoring the available treatment options according to the 
disease phenotype is needed to ensure the use of a minimal combination of drugs for a maximal 
therapeutic effect (1). Conventional treatments for PsA have limited efficacy for nail disease, enthesitis 
or axial involvement, and some are unable to control moderate and severe peripheral joint and skin 
disease. For the first time, the introduction of biologic treatments offered the possibility of controlling 
multiple aspects of these diseases using a single drug, minimising the need for additional therapies.
Discussion
The new biologics reassuringly showed similar control of peripheral joint symptoms (indirect 
comparison showed the following percentages of ACR 20 response: Ustekinumab 90 mg, 42%; 
Secukinumab 300 mg, 54%; Brodalumab 280 mg, 64%: Abatacept 10 mg/kg, 48%; Apremilast 20 mg 
daily, 43.5%, which is comparable to Infliximab 5 mg/kg, 65%; Certolizumab 200 mg e.o.w., 58%; 
Golimumab 100 mg monthly, 61%; Adalimumab 58%, Etanercept 25 mg twice weekly, 59%).
Different aspects of the disease activity, such as dactylitis and enthesitis, were effectively controlled by 
anti TNF therapy, and also by Ustekinumab and Secukinumab.
The axial involvement also responded to therapy with Ustekinumab and Secukinumab. 
The nail involvement, enthesitis and dactylitis associated were all improved with treatment with 
Apremilast and Secukinumab, (along with Infliximab, Certolizumab, Etanercept, Adalimumab and 
Golimumab).
Optimising therapy for those patients who failed anti-TNF treatments is one of the main challenges. 
Dose adjustment of Secukinumab showed the best response in PsA patients previously treated with 
anti TNF therapy (2).
The response to a second anti TNF agent, in patients with PsA who failed the first anti TNF, is 
significantly lower (3); the use of other biologic treatments with different mechanisms of action is 
therefore currently considered a better option.
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Materials and Methods
A systematic literature research of MEDLINE (via PubMed) and EMBASE data bases (from July 2000 
to March 2015) was performed to identify randomised controlled trials (RCT) that reported the efficacy 
of different biologic therapies in psoriasis and PsA. We used the following MeSH terms: Anti-TNF 
treatments (adalimumab, etanercept, infliximab, golimumab, certolizumab), Anti-IL12/23 
(ustekinumab), Anti-co-stimulatory molecule (abatacept), Phosphodiesterase-4-inhibitor (apremilast), 
Anti-IL17 (secukinumab, brodalumab, ixekizumab,), Anti-IL6 (tocilizumab), T-cell modulator 
(alefacept), Anti-CD11a (efalizumab), Janus-kinase-inhibitor (tofacitinib), Anti-CD20 (rituximab), Anti-
CD6 (itolizumab), and psoriasis and psoriatic arthritis. Only papers in English were selected. SE and 
BT screened all titles and abstracts for potential inclusion. 
We identified 1718 papers including RCT of biologic treatments in psoriasis and PsA. Duplications or 
papers analysing the same RCT were excluded. Congress abstracts and case reports were included 
only for the new emerging therapies, because of the lack of clinical trial data available.  
We selected 88 papers, which were analysed in detail, out of which 40 papers were included in table 
1.
Results
The table below includes a summary of biologic treatments and their efficacy for different clinical 
manifestations in PsA and psoriasis, using the following level of evidence classification (Oxford Centre 
of Evidence-based Medicine, 2009):
1a: Systematic reviews (with homogeneity) of randomized controlled trials
1b: Individual randomized controlled trials (with narrow confidence interval)
1c: “All or none” randomized controlled trials
2a: Systematic reviews (with homogeneity) of cohort studies
2b: Individual cohort study or low quality randomized controlled trials (e.g. <80% follow-up)
2c: "Outcomes" Research; ecological studies
3a: Systematic review (with homogeneity) of case-control studies
3b: Individual case-control study
4: Case-series (and poor quality cohort and case-control studies)
5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first 
principles"
Conclusion
1. Ustekinumab can be used as second line biologic in psoriatic and PsA patients who failed TNF 
treatments (level of evidence 1b)
2. Secukinumab at higher dose (300 mg) and with additional IV loading dose is effective in PsA 
patients who failed anti TNF therapy (level of evidence 1b)
3. The use of a second anti TNF therapy can be effective in patients who failed the first anti TNF 
treatment (Certolizumab and Golimumab, level of evidence 1b; Infliximab and Adalimumab and 
Etanercept- level of evidence 2b)
It is difficult to establish an algorithm for sequential biologic treatment in PsA patients who failed the 
first biologic, due to of lack of evidence of efficacy of the majority of new drugs as second line biologic 
therapies.
Treatment Peripheral Arthritis Sacroiliitis & Spinal Disease Enthesitis Dactylitis Nail Involvement Skin Psoriasis
ADALIMUMAB YES (*1a)    YES (*1a) YES (*1a)
ETANERCEPT YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
ABATACEPT YES (*1b) NO (*1b)- study in AS    YES (*1b)
APREMILAST YES (*1a)  YES (*1b) YES (*1b) YES (*1b) YES (*1a)
ALEFACEPT      YES (*1a)
EFALIZUMAB
(withdrawn)
NO (*1b)     YES (*1a)
BRODALUMAB YES (*1b) YES (*1b) NO (*1b) NO (*1b)   
INFLIXIMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
IXEKIZUMAB Ongoing study  Ongoing study Ongoing study Ongoing study YES (*1a)
CERTOLIZUMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
GOLIMUMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
ITOLIZUMAB Planned studies Planned studies Planned studies Planned studies Planned studies YES (*1b)
RITUXIMAB NO (*1b)  YES (*1b) NO (*1b)   
SECUKINUMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a)   
TOCILIZUMAB YES (*4) NO (*1b)    YES(pustular psoriasis) (*4)
TOFACITINIB Ongoing studies Under recruitment in AS Ongoing studies Ongoing studies  YES (*1a)
USTEKINUMAB YES (*1a) YES (*1b) YES (*1b) YES (*1b)  YES (*1a)
